
Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes

Introduction Artificial intelligence continues to push healthcare into a new era from early disease detection to large-scale data modelling. Yet

How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency

Volv Global at WODC Europe 2025 – Where Technology Meets Human Volv Global sits at the crucial intersection between technology

Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Recently, I had powerful thought come to me on reading

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical

By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition

Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to

Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out

By Léon Van Wouwe, Clinical Innovation Director, Volv Global Gastric (stomach) cancer remains a formidable global health challenge, ranking